STING agonist-26 (CF508) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains.
STING agonist-26 (10 μM; 3 h or 5 h) increases the level of phosphorylated STING, TBK1 and IRF3 following 3-h incubation, increases the level of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15 following 5-h incubation, and CCL-5, in THP-1 cells[1].
STING agonist-26 adjuvant (20 μg STING agonist-26 and 5 μg RBD-Fc per mouse; im; 3 times at 14-day intervals) induces strong antibody immune response induced by the SARS-CoV-2 RBD-Fc protein in mice model[1].
References:
[1]. Liu Z, et al. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Cell Res. 2022 Mar;32(3):269-287.